- Continued improvement in revenues and cost savings
- Margins remain high in the local services
- US growing with THRiV in high demand from pharma
- No mention of Charac (UK)
- FY23H2 was $34M (roughly even between quarters)
- FY24Q3 revenue $24M may project same or more in Q4 (FY Revenue ~$125M)
- MDR market cap $150M with above FY revenue estimate ($125M)
- ALC market cap $60M on $35M annual revenue (if lucky!)
- Management have demonstrated YoY growth for a number of years
- Will Luke and Claude change their tune?
- Will the market recognise profitability and success in the US?
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
6.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $40.01M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35556 | 6.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.6¢ | 190000 | 1 |
View Market Depth
| Last trade - 16.21pm 08/08/2025 (20 minute delay) ? |
| MDR (ASX) Chart |
Day chart unavailable